Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease
AffiliationUniversity of Arizona Cancer Center
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona
Division of Hematology/Oncology, Department of Medicine, University of Arizona Cancer Center
Department of Pathology, College of Medicine, University of Arizona
MetadataShow full item record
PublisherBioMed Central Ltd
CitationVrba, L., Futscher, B. W., Oshiro, M., Watts, G. S., Menashi, E., Hu, C., Hammad, H., Pennington, D. R., Golconda, U., Gavini, H., Roe, D. J., Shroff, R. T., & Nelson, M. A. (2022). Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease. Clinical Epigenetics.
RightsCopyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractWe tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients. © 2022, The Author(s).
NoteOpen access journal
VersionFinal published version
Except where otherwise noted, this item's license is described as Copyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.
- A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer.
- Authors: Shinjo K, Hara K, Nagae G, Umeda T, Katsushima K, Suzuki M, Murofushi Y, Umezu Y, Takeuchi I, Takahashi S, Okuno Y, Matsuo K, Ito H, Tajima S, Aburatani H, Yamao K, Kondo Y
- Issue date: 2020
- SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
- Authors: Manoochehri M, Wu Y, Giese NA, Strobel O, Kutschmann S, Haller F, Hoheisel JD, Moskalev EA, Hackert T, Bauer AS
- Issue date: 2020 Jun
- Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma.
- Authors: Henriksen SD, Madsen PH, Larsen AC, Johansen MB, Drewes AM, Pedersen IS, Krarup H, Thorlacius-Ussing O
- Issue date: 2016
- Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer.
- Authors: Melson J, Li Y, Cassinotti E, Melnikov A, Boni L, Ai J, Greenspan M, Mobarhan S, Levenson V, Deng Y
- Issue date: 2014 Jun 1
- Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients.
- Authors: Miller BF, Petrykowska HM, Elnitski L
- Issue date: 2021 Jan 8